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A B S T R A C T :
Primary Hyperoxaluria Type I (PH1) is a rare autosomal recessive metabolic disorder characterized by defects in enzymes involved in glyoxylate metabolism. PH1 is a
life-threatening disease caused by the absence, deficiency or mistargeting of the hepatic alanine-glyoxylate aminotransferase (AGT) enzyme. A human induced
pluripotent stem cell (iPSC) line was generated from dermal fibroblasts of a PH1 patient being compound heterozygous for the most common mutation c.508G>A
(G170R), a mistargeting mutation, and c.364C>T (R122*), a previously reported nonsense mutation in AGTX. This iPSC line offers a useful resource to study the
disease pathophysiology and a cell-based model for drug development.
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Juan R. Rodriguez-Madoz (jrrodriguez@unav.es)
Type of cell line iPSC
Origin Human
Additional origin info Age: 30 years
Sex: Male
Ethnicity: Caucasian




Transgene free (CytoTune™-iPS 2.0 Sendai
Reprogramming Kit)
Genetic Modification YES
Type of Modification Inherited
Associated disease Primary hyperoxaluria type I
Gene/locus AGXT c.508G>A (G170R) and c.364C>T (R122*)
Method of modification N/A












Ethical approval Patient informed consent obtained by the Ethical
Committee of Clinical Investigation of Clinica Universidad
de Navarra (Approval no. 171/2014)
Resource utility
This human induced pluripotent stem cell (iPSC) line is a useful tool
for studies of disease phenotype and pathophysiology, and to be used as
a cell-based disease model for drug development to treat PH1 patients.
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Primary Hyperoxalurias (PH) are a group of rare autosomal re-
cessive metabolic disorders characterized by defects in enzymes
involved in glyoxylate metabolism. Primary hyperoxaluria type 1
(PH1), the most common form, is a life-threatening disease with an
estimated prevalence of 1 to 3 cases per 1 million population, caused by
the absence, deficiency or mistargeting of the hepatic alanine-
Figure 1. Characterization of PH1-iPSC-G170R line. (A) Typical round shape colony morphology with small, tightly packed cells and expression of pluripotency-
associated markers (SOX2, OCT4, NANOG and SSEA4) by immunofluorescence. (B) Expression of endogenous pluripotency-associated markers DPPA4, LIN28A,
NANOG, POU5F1, ZFP42 and SOX2 were confirmed by qPCR. (C) Genotyping of the PH1-iPSC-G170R line. Presence of the c.364C>T (R122*) and c.508G>A
(G170R) mutations in AGXT gene were analyzed by sequencing. (D) Karyotype analysis of PH1-iPSC-G170R line depicting a normal 46XY karyotype. (E) Analysis if
the differentiation capacity into three germ layers measured by qPCR using STEMdiff™ Trilineage Differentiation Kit (StemCell technologies).
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glyoxylate aminotransferase (AGT) enzyme (Cochat and Rumsby,
2013).
In this study we have generated an induced pluripotent stem cell
(iPSC) line from dermal fibroblasts of a 30-year-old male primary hy-
peroxaluria type I (PH1)-diagnosed patient carrying compound het-
erozygous c.364C>T (R122*) and c.508G>A (G170R) mutations in
AGXT gene. PH1-iPSC-G170R line was generated using the non-
integrating CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo
Scientific, Invitrogen), which includes the reprogramming factors
SOX2, POU5F1, cMYC and KLF4. This reprogramming system is based
on a modified and non-transmissible form of Sendai virus (SeV) (Ban
et al., 2011). PH1-iPSC-G170R line displayed a typical round shape
ESC-like morphology with small and tightly packed cells, with a high
nucleus/cytoplasm ratio and prominent nucleoli (Fig. 1A). The
Table 1
Characterization and validation
Classification Test Result Data
Morphology Photography Normal Figure 1 panel A
Phenotype Qualitative analysis:
Immunofluorescence
SOX2, OCT4, NANOG, SSEA-4 Figure 1 panel A
Quantitative analysis:
RT-qPCR
DPPA4, LIN28A, NANOG, POU5F1 (OCT4), ZFP42 (REX1), SOX2 Figure 1 panel B
Genotype Karyotype (G-banding) and resolution Normal 46XY
Resolution 400
Figure 1 panel D
Identity Microsatellite PCR (mPCR) N/A N/A




Sequencing Compound heterozygous mutation of AGXT p.R122*, p.G170R Figure 1 panel C
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence. Negative Supplementary Fig. S1B
Differentiation potential Directed differentiation (STEMdiff™
Trilineage Differentiation kit)
Confirmation of gene expression of ectodermal (NES, PAX6, GFAP,
TUBB3), mesodermal (TBXT, MIXL1, FN1, MESP1) and endodermal
(CXCR4, EOMES, FOXA2, SOX17) markers.
Figure 1 panel E
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 2
Reagents details
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-NANOG 1:100 Abcam Cat# ab80892, RRID:AB_2150114
Pluripotency Markers Rabbit anti-SOX2 1:500 Millipore Cat# AB5603, RRID:AB_2286686
Pluripotency Markers Rabbit anti-OCT4 1:50 Santa Cruz Biotechnology Cat# sc-9081, RRID:AB_2167703
Pluripotency Markers Mouse anti-SSEA4 1:1000 Cell signaling, Cat# 4755, RRID: AB_1264259
Secondary antibodies Alexa Fluor 594 donkey anti-rabbit IgG 1:1000 Thermo Fisher, Cat# A21207, RRID: AB_141637
Secondary antibodies Alexa Fluor 488 goat anti-rabbit IgG 1:200 Thermo Fisher, Cat# A11008, RRID: AB_143165
Secondary antibodies Alexa Fluor 488 donkey anti-mouse IgG 1:200 Thermo Fisher, Cat# A21202, RRID: AB_141607
Primers
Target Forward/Reverse primer (5′-3′)
Pluripotency Markers DPPA4 TGGTGTCAGGTGGTGTGTGG / CCAGGCTTGACCAGCATGAA
Pluripotency Markers LIN28A GGAGGCCAAGAAAGGGAATATGA / AACAATCTTGTGGCCACTTTGACA
Pluripotency Markers NANOG CCTGTGATTTGTGGGCCTG / GACAGTCTCCGTGTGAGGCAT
Pluripotency Markers POU5F1 GGAAGGAATTGGGAACACAAAGG / AACTTCACCTTCCCTCCAACCA
Pluripotency Markers ZFP42 TGGAGCCTGTGTGAACAGAA / CCACCTCCAGGCAGTAGTGA
Pluripotency Markers SOX2 TGGCGAACCATCTCTGTGGT / CCAACGGTGTCAACCTGCAT
Pluripotency Markers CDH1 GAGTGCCAACTGGACCATTC / ACCCACCTCTAAGGCCATCT
Ectodermal Markers PAX6 CCCCACATATGCAGACACAC / TCACTTCCGGGAACTTGAAC
Ectodermal Markers NES CGTTGGAACAGAGGTTGGAG / GAGCGATCTGGCTCTGTAGG
Ectodermal Markers GFAP TGGAGGTTGAGAGGGACAAT / TAGGCAGCCAGGTTGTTCTC
Ectodermal Markers TUBB3 GGCCTTTGGACATCTCTTCA / GACCGAATCCACCAGCTC
Mesodermal Markers TBXT ACTCACCTGCATGTTTATCCA / CCGTTGCTCACAGACCACAG
Mesodermal Markers MIXL1 GGTACCCCGACATCCACTT / GCCAAAGGTTGGAAGGATTT
Mesodermal Markers MESP1 GAAGGGCAGGCGATGGAG / CAGGCAGCCACTCCAGAG
Mesodermal Markers FN1 CCCCATTCCAGGACACTTCT / TGCCTCCACTATGACGTTGT
Endodermal Markers CXCR4 GGTGGACATTCATCTGTTTCC / CAAGACAAAAATCCAACAAGCA
Endodermal Markers EOMES GGCAAAGCCGACAATAACAT / TTCCCGAATGAAATCTCCTG
Endodermal Markers FOXA2 CACTCGGCTTCCAGTATGCT / GTTCATGTTGCTCACGGAGG
Endodermal Markers SOX17 GAATCCAGACCTGCACAACG / CTCTGCCTCCTCCACGAAG
House-Keeping Gene GAPDH CTGGTAAAGTGGATATTGTTGCCAT / TGGAATCATATTGGAACATGTAAACC
Mutation analysis AGXT c.508G>A (p.G170R) CTCAGCCTACCCGGAGTGTG /GGAGGGAAGTGGAGGGCATC
Mutation analysis AGXT c.364C>T (p.R122*) CACCCTCCTCTTCAGGCAGG /AGGACCAGGCTCCTGACTCA
Sev specific primers SeV GGATCACTAGGTGATATCGAGC / ACCAGACAAGAGTTTAAGAGATATGTATC
Sev specific primers SeV_KOS ATGCACCGCTACGACGTGAGCGC / ACCTTGACAATCCTGATGTGG
Sev specific primers SeV_K TTCCTGCATGCCAGAGGAGCCC / AATGTATCGAAGGTGCTCAA
Sev specific primers SeV_M TAACTGACTAGCAGGCTTGTC / TCCACATACAGTCCTGGATGATGATG
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presence of the c.508G>A and c.364C>T mutations in AGXT gene was
confirmed (Fig. 1C) and the expression of several pluripotency-asso-
ciated markers was corroborated by qPCR (Fig. 1B) and immuno-
fluorescence (Fig. 1A). Moreover, the absence of exogenous repro-
gramming transgenes was observed by RT-PCR after 10 passages
(Supplementary Fig. S1A). Differentiation capacity into three germ
layers was demonstrated by trilineage differentiation (Fig. 1E). Finally,
PH1-iPSC-G170R line showed normal karyotype (46, XY) (Fig. 1D), was
not contaminated with mycoplasma (Supplementary Fig. S1) and cell
line identity was corroborated using a short tandem repeat (STR) DNA
analysis, which demonstrated matching genotypes at all 16 loci ex-
amined.
Materials and Methods
Ethical approval. All procedures were approved by the University
of Navarra Ethical Committee and by the Advisory Committee for
Human Tissue and Cell Donation and Use, according to Spanish and EU
legislation. Fibroblast were obtained after written informed consent.
Cell culture. Fibroblasts were obtained from a skin biopsy by direct
seeding of small tissue fragments under coverslips. Cells were cultured
in gelatin-coated culture plates for a maximum of five passages before
reprogramming in DMEM (Sigma) supplemented with 10% FBS
(Gibco), 0.1 mM NEAA(Gibco), 2 mM L-glutamine (Lonza), and 100 UI/
ml P/S (Lonza).
PH1-iPSC-G170R generation. Patient fibroblasts were repro-
grammed using CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo
Scientific, Invitrogen). iPSCs were cultured at 37ºC and 5%CO2 under
feeder-free conditions using Matrigel™-coated culture dishes (BD
Biosciences) and mTeSR™1 (StemCell Technologies). iPSCs were rou-
tinely passaged using ReLeSR™ (StemCell Technologies) at a splitting
ratio of 1:3 or 1:6 every week when cells reached confluence (Fig. 1A).
Genomic DNA extraction and genotyping. Genomic DNA was
isolated from PH1-iPSC-G170R and parental cells using NucleoSpin
tissue kit (Macherey-Nagel). For genotyping 50 ng of DNA was ampli-
fied on a SimpliAmp™ Thermal Cycler (Applied Biosystems) using
Platinum® Taq DNA Polymerase HF (Invitrogen) by specific primers
(Table 2) with the following conditions: 95ºC 2’, [95ºC 20’’, 63ºC 20’’,
72ºC 40’’]x40, 72ºC 3’. The presence of the c.364C>T (R122*) and
c.508G>A (G170R) mutations in AGXT gene were analyzed in the PCR
purified products (456bp and 751bp respectively) by sequencing
(Fig. 1C).
Trilineage differentiation. Directed differentiation into three germ
layers was achieved using STEMdiff™ Trilineage Differentiation Kit
(StemCell technologies) according to manufacturer's instructions. In
brief, PH1-iPSC-G170R line was seeded at recommended cell densities
onto Matrigel™-coated culture dishes (BD Biosciences). Cells were cul-
tured in lineage specific medium with daily medium changes until day
5 for meso- and endodermal and until day 7 for ectodermal differ-
entiation, respectively. Expression of lineage specific markers was
performed by qPCR as described below.
RNA extraction and RT-qPCR. Total RNA was isolated with
Maxwell® 16 LEV simplyRNA Tissue Kit (Promega). RNA concentration
was determined using a NanoDrop (Thermo Scientific) and RNA quality
tested using Bioanalyzer (Agilent). cDNA was synthesized using
PrimeScriptTM-RT reagent Kit (Takara). qPCR primers (Table 2) were
designed using Primer3 input software. Expression of pluripotency-as-
sociated and linage-specific markers was evaluated in 10ng of cDNA by
qPCR using PowerUp™ SYBR® Green Master Mix (Applied Biosystems)
on a QuantStudio 5 Real-Time PCR System (Applied Biosystems) with
the following parameters: 50ºC 2’, 95ºC 10’, [95ºC 15’’, 60ºC 1’]x40,
melting curve 60ºC-95ºC. Data was analyzed using delta-CT method.
Gene expression levels were normalized to GAPDH expression (Fig. 1B).
Silencing of the exogenous reprogramming factors was analyzed fol-
lowing CytoTune™-iPS 2.0 manufacturer's instructions (Supplementary
Fig. S1A).
Immunofluorescence (IF). IF was performed as described (Zapata-
Linares et al., 2016). Briefly, PH1-iPSC-G170R was fixed with 4% PFA
(Sigma), permeabilized for 10 minutes with 1% TritonX-100 (Sigma) in
PBS and blocked with 5% BSA for 30 minutes. SOX2 (Millipore),
POU5F1 (Santa Cruz), NANOG (Abcam) and SSEA-4 (Cell Signalling)
primary antibodies were diluted in PBS/TBS with 1% BSA and in-
cubated for one hour at RT. Alexa Flour-488- and Alexa Fluor-594-
conjugated secondary antibodies (Thermo Fisher) were incubated for 1-
1.5 hours at RT. Samples were visualized under an inverted fluores-
cence microscope (Nikon Eclipse Ti-S) (Fig. 1A). Antibodies used and
dilutions are listed in Table 2.
Karyotype analysis. Chromosomal analysis was performed on
PH1-iPSC-G170R line at passage 20-22 by GTG-banding analysis at 400
bands of resolution on 20 metaphase spreads at the Molecular
Cytogenetics Group, Spanish National Cancer Centre-CNIO, according
to the International System Cytogenetics Nomenclature recommenda-
tions.
Short tandem repeat (STR) analysis. STR analysis of PH1-iPSC-
G170R line and its parenteral fibroblast was performed at CIMA LAB
Diagnostics using AmpFlSTR® Identifiler® PCR Amplification Kit
(Applied Biosystems). Multiplex PCR performed for the STRs D8S1179,
D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539,
D2S1338, D19S433, vWA, TPOX, D18S51, AMEL, D5S818 and FGA
confirmed cell identity.
Mycoplasma detection. Mycoplasma testing was performed and
analyzed using the Lonza MycoAlert kit. Ratio B/A > 1.2 indicates
mycoplasma positive. Ratio B/A 0.9–1.2 indicates ambiguous results
and Ratio B/A < 0.9 indicates mycoplasma negative (Supplementary
Fig. S1B).
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